Sonic hedgehog maintains survival and growth of chronic myeloid leukemia progenitor cells through 尾-catenin signaling

详细信息	查看全文 | 推荐本文 |

• 作者：Wenxia Su ; Fankai Meng ; Lifang Huang ; Miao Zheng ; Wenli Liu ; Hanying Sun ; ^{hanyingsun@sina.com}
• 刊名：Experimental Hematology
• 出版年：2012
• 期刊代码：100_0301472x
• 类别：med
• 出版时间：May, 2012
• 卷：40
• 期：5
• 页码：418-427
• 文件大小：1005 K

摘要

Sonic hedgehog (Shh) signaling plays an important role in many human cancers and cancer stem cells. Here we investigate the activity and functional role of Shh signaling in chronic myeloid leukemia (CML) and leukemia progenitor cells. Differential activation of Shh signaling was found in about 50%CML chronic phase samples, about 70%of CML accelerated phase samples, and >80%CML blast crisis phase samples. Deregulated activation of Shh signaling was observed in CD34⁺ and c-kit⁺ leukemia progenitor cells. Stimulation of Shh signaling with exogenous Shh peptide induced expansion of CD34⁺ and c-kit⁺ progenitor cells (p < 0.05), inversely, blocking the pathway with signal inhibitor induced cell apoptosis (p < 0.05). Low level of Shh protein was observed in CML bone marrow stromal cells, and CD34⁺ progenitor cells are less sensitive to exogenous Shh peptide and more sensitive to cyclopamine than CD34^{鈭?/sup> cells (p < 0.05), implying cell-autonomous activation of Shh signaling play a predominant role in progenitor cells. Coactivation of Shh and 尾-catenin signaling was found in CD34+ and c-kit+ progenitor cells. Administration of Shh-neutralizing antibody or Wnt3a-neutralizing antibody in c-kit+ progenitor cells induced cell apoptosis; however, Wnt3a peptide could salvage cell apoptosis, while Shh peptide failed to revert anti鈭扺nt3a-induced cell apoptosis. C-MYC, GLI1, BCL-2, and P21 were also found to be downstream targets of Shh signaling, mediating apoptosis or G₂/M cell cycle arrest of progenitor cells. Our results demonstrate that autoactivated Shh signaling provides survival and proliferative cues in CML progenitor cells through downstream 尾-catenin signaling, suggesting a novel therapeutic approach in CML.}